Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vixarelimab in Moderate to Severe Ulcerative Colitis
CTR20241947Phase 2Terminated
- Sponsor
- Genentech
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of vixarelimab in autoimmune colitis, sponsored by Genentech. Started Jun 2024; status: terminated.
02
Drugs
vixarelimab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20241947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241947.